Clinical Trials Logo

Lymphoma, Extranodal NK-T-Cell clinical trials

View clinical trials related to Lymphoma, Extranodal NK-T-Cell.

Filter by:

NCT ID: NCT01787409 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

Start date: March 6, 2013
Phase: N/A
Study type: Interventional

This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient.

NCT ID: NCT01667302 Recruiting - Clinical trials for Extranodal NK/T-cell Lymphoma, Nasal Type

Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma

Start date: June 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and tolerability of radiotherapy followed by adjuvant chemotherapy in stage I/II NK/T-cell lymphoma.

NCT ID: NCT00725231 Recruiting - Clinical trials for Extranodal NK/T-cell Lymphoma

Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP

A-CHOP-14
Start date: February 2008
Phase: Phase 3
Study type: Interventional

Peripheral T cell lymphomas comprise 10-15% of all malignant lymphomas. The prognosis is significantly worse than that of aggressive B cell lymphomas. The prospects of elderly patients are especially poor, with an estimated disease free survival of only 25% after three years. Previous phase II trials have demonstrated a significant activity of the monoclonal anti CD52 antibody alemtuzumab in primary and relapsed T cell lymphoma. The investigators thus propose to investigate the value of adjuvant alemtuzumab in combination with dose dense CHOP-14 in patients with previously untreated peripheral T cell lymphoma.